Skip to main content

Table 5 The median (range) values of methylation of studied CpG sites and chosen gene expression

From: Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival

Analysis AML patient MNCs
Median (range) [number of patient]
Control MNCs
Median (range) [number of sample]
Methylation (%)
 CG6 88.28 (5.00–99.53) [44] 60.89 (48.75–70.89) [9]
 CG7 74.45 (32.65–97.69) [42] 60.21 (24.98–72.70) [9]
 CG8 91.91 (30.43–99.65) [44] 65.65 (60.11–82.36) [9]
 CG9 55.34 (7.86–91.73) [42] 46.53 (39.23–60.13) [8]
ZAC 49.24 (18.96–71.97) [42] 62.91 (46.50–78.97) [8]
IGF2-H19 70.20 (40.97–99.56) [45] 78.12 (68.64–86.20) [9]
PEG3 67.18 (15.95–98.10) [42] 67.41 (41.82–79.71) [9]
PEG1 56.29 (23.08–95.13) [45] 66.74 (57.85–68.91) [9]
Expression (∆Ct)
DLK1 (× 10−7) 50.98 (0.88–161,542.28) [29]  
MEG3 (× 10− 6) 34.189 (1.36–19,339.85) [29]  
DLK1/MEG3 (× 10− 2) 10.31 (0.20–1121.10) [29]